评述："PSCA CAR 工程化 Vδ1 γδ T 细胞用于胰腺癌免疫治疗的疗效与安全性比较"

Commentary on "Comparative efficacy and safety of PSCA CAR-engineered Vδ1 γδ T cells for immunotherapy of pancreatic cancer".

设计更优：新型 CAR 工程化细胞疗法可期待什么？

Better by design: What to expect from novel CAR-engineered cell therapies?

超越 CAR-T 细胞：探索 CAR-NK、CAR-M 与 CAR-γδ T 策略在实体瘤免疫治疗中的应用

Beyond CAR-T Cells: exploring CAR-NK, CAR-M, and CAR-γδ T strategies in solid tumor immunotherapy.

肿瘤细胞治疗的进展与前景：从 T 细胞到干细胞的探索

Advances and prospects in cell therapy for cancer: explorations from T cells to stem cells.

细胞毒性和检查点受体的双重调节可调控过继性 Delta One T 细胞疗法对结直肠癌的疗效

Dual modulation of cytotoxic and checkpoint receptors tunes the efficacy of adoptive Delta One T cell therapy against colorectal cancer.

经磷脂酰肌醇蛋白聚糖-3 (GPC-3) 特异性嵌合抗原受体 (CAR) 和可溶性 IL-15 工程化的现货型 Vδ1 γδ T 细胞对肝细胞癌显示强效抗肿瘤疗效

Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust ant

经 GPC-3 CAR 和 sIL-15 工程化改造的扩增 V 1 T 细胞代表一个有前景的平台，值得进一步开展临床评估，作为 HCC 以及可能其他表达 GPC-3 的实体瘤的现货型治疗。

TGF-β阻断剂 SB525334 增强 B7-H3 CAR-γδT 细胞对胶质母细胞瘤的疗效

TGF-β Blockade With SB525334 Enhances B7-H3 CAR-γδT Cell Efficacy Against Glioblastoma.

标准切除术后化疗和放疗后同步替莫唑胺与颅内 MGMT 修饰 γδ T 细胞的过继细胞治疗用于高级别胶质瘤：当前策略与未来方向

Adoptive cell therapy for high grade gliomas using simultaneous temozolomide and intracranial mgmt-modified γδ t cells following standard post-resecti

ADI-270：一种旨在靶向表达 CD70 的实体瘤和血液系统恶性肿瘤的装甲型异体 γδ T 细胞疗法

ADI-270: an armored allogeneic gamma delta T cell therapy designed to target CD70-expressing solid and hematologic malignancies.

这些结果证明了 ADI-270 具有强大的效力和能力，可将抗肿瘤活性扩展至抗原表达异质性的癌症。ADI-270 中引入的功能性装甲提供了一种机制，用以克服 TME 内疗效降低和持续性受限的局限。ADI-270 有潜力靶向多种 CD70 + 癌症，初步临床评估正在复发/难治性透明细胞肾细胞癌中开展。

γδ T 细胞：起源与命运、亚群、疾病与免疫治疗

γδ T cells: origin and fate, subsets, diseases and immunotherapy.